Total Payments
$690.36
2024 Payments
$29.15
Companies
10
Transactions
47
Medicare Patients
1,829
Medicare Billing
$869,854
Payment Breakdown by Category
Food & Beverage$690.36 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $690.36 | 47 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sunovion Pharmaceuticals Inc. | $211.56 | 18 | $0 (2021) |
| AbbVie Inc. | $135.59 | 9 | $0 (2023) |
| Allergan, Inc. | $77.67 | 5 | $0 (2020) |
| Supernus Pharmaceuticals, Inc. | $67.79 | 5 | $0 (2022) |
| Axsome Therapeutics, Inc. | $49.17 | 2 | $0 (2023) |
| Lundbeck LLC | $47.71 | 3 | $0 (2021) |
| Otsuka America Pharmaceutical, Inc. | $35.42 | 2 | $0 (2022) |
| Neurocrine Biosciences, Inc. | $29.15 | 1 | $0 (2024) |
| Ironshore Pharmaceuticals Inc. | $21.78 | 1 | $0 (2019) |
| Eisai Inc. | $14.52 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $29.15 | 1 | Neurocrine Biosciences, Inc. ($29.15) |
| 2023 | $111.99 | 6 | AbbVie Inc. ($62.82) |
| 2022 | $60.70 | 4 | ABBVIE INC. ($29.05) |
| 2021 | $212.71 | 13 | Sunovion Pharmaceuticals Inc. ($85.85) |
| 2020 | $94.63 | 6 | Allergan, Inc. ($43.98) |
| 2019 | $149.21 | 13 | Sunovion Pharmaceuticals Inc. ($93.74) |
| 2017 | $31.97 | 4 | Sunovion Pharmaceuticals Inc. ($31.97) |
All Payment Transactions
47 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/29/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $29.15 | General |
| Category: Neuropsychiatry | ||||||
| 10/17/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.57 | General |
| Category: NEUROSCIENCE | ||||||
| 05/09/2023 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $27.64 | General |
| Category: Psychology/Psychiatric | ||||||
| 04/18/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.89 | General |
| Category: NEUROSCIENCE | ||||||
| 04/04/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.88 | General |
| Category: NEUROSCIENCE | ||||||
| 02/13/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.48 | General |
| Category: NEUROSCIENCE | ||||||
| 01/05/2023 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $21.53 | General |
| Category: Psychology/Psychiatric | ||||||
| 10/11/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.02 | General |
| Category: NEUROSCIENCE | ||||||
| 07/20/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.03 | General |
| Category: NEUROSCIENCE | ||||||
| 04/28/2022 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $17.59 | General |
| Category: PSYCHIATRY | ||||||
| 02/12/2022 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $14.06 | General |
| Category: PSYCHOLOGY | ||||||
| 12/10/2021 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $11.85 | General |
| Category: PSYCHOLOGY | ||||||
| 12/02/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.26 | General |
| Category: NEUROSCIENCE | ||||||
| 11/18/2021 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $23.97 | General |
| Category: CNS | ||||||
| 11/09/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.33 | General |
| Category: NEUROSCIENCE | ||||||
| 11/01/2021 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $11.84 | General |
| Category: PSYCHOLOGY | ||||||
| 10/12/2021 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $17.75 | General |
| Category: PSYCHIATRY | ||||||
| 08/17/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.13 | General |
| Category: NEUROSCIENCE | ||||||
| 07/29/2021 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $12.72 | General |
| Category: PSYCHOLOGY | ||||||
| 06/16/2021 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $17.32 | General |
| Category: PSYCHOLOGY | ||||||
| 05/04/2021 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $11.66 | General |
| Category: PSYCHIATRY | ||||||
| 03/30/2021 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $24.19 | General |
| Category: CNS | ||||||
| 02/11/2021 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $13.13 | General |
| Category: CNS | ||||||
| 01/14/2021 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $24.56 | General |
| Category: CNS | ||||||
| 12/02/2020 | Eisai Inc. | Dayvigo (Drug) | Food and Beverage | Cash or cash equivalent | $14.52 | General |
| Category: Neurology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 415 | 3,525 | $508,648 | $226,401 |
| 2022 | 5 | 464 | 3,351 | $464,592 | $202,639 |
| 2021 | 5 | 449 | 3,457 | $404,275 | $216,949 |
| 2020 | 7 | 501 | 3,449 | $419,190 | $223,864 |
Total Patients
1,829
Total Services
13,782
Medicare Billing
$869,854
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 186 | 2,599 | $288,489 | $152,574 | 52.9% |
| 90870 | Therapy using electrical currents | Facility | 2023 | 30 | 669 | $169,257 | $53,308 | 31.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 123 | 149 | $33,972 | $13,821 | 40.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 36 | 47 | $8,695 | $3,439 | 39.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 40 | 61 | $8,235 | $3,259 | 39.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 211 | 2,370 | $252,734 | $126,486 | 50.0% |
| 90870 | Therapy using electrical currents | Facility | 2022 | 27 | 660 | $155,884 | $50,392 | 32.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 114 | 140 | $29,779 | $13,650 | 45.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 62 | 115 | $14,650 | $6,601 | 45.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 50 | 66 | $11,545 | $5,510 | 47.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 217 | 2,429 | $230,755 | $132,590 | 57.5% |
| 90870 | Shock treatment and monitoring | Facility | 2021 | 29 | 720 | $129,600 | $58,472 | 45.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 111 | 148 | $24,320 | $14,514 | 59.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 45 | 72 | $10,800 | $6,344 | 58.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 47 | 88 | $8,800 | $5,028 | 57.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 214 | 2,247 | $213,465 | $124,953 | 58.5% |
| 90870 | Shock treatment and monitoring | Facility | 2020 | 32 | 822 | $147,960 | $68,807 | 46.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 141 | 181 | $29,645 | $18,391 | 62.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 45 | 111 | $14,050 | $5,753 | 40.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 41 | 59 | $8,850 | $3,564 | 40.3% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2020 | 14 | 15 | $3,750 | $1,615 | 43.1% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 14 | 14 | $1,470 | $780.83 | 53.1% |
About Dr. Christopher Stanley, MD
Dr. Christopher Stanley, MD is a Psychiatry healthcare provider based in Lexington, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/06/2007. The National Provider Identifier (NPI) number assigned to this provider is 1689865461.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Stanley, MD has received a total of $690.36 in payments from pharmaceutical and medical device companies, with $29.15 received in 2024. These payments were reported across 47 transactions from 10 companies. The most common payment nature is "Food and Beverage" ($690.36).
As a Medicare-enrolled provider, Stanley has provided services to 1,829 Medicare beneficiaries, totaling 13,782 services with total Medicare billing of $869,854. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Lexington, KY
- Active Since 08/06/2007
- Last Updated 08/06/2007
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1689865461
Products in Payments
- VRAYLAR (Drug) $213.26
- LATUDA (Drug) $211.56
- QELBREE (Drug) $67.79
- REXULTI (Drug) $64.83
- Auvelity (Drug) $49.17
- INGREZZA (Drug) $29.15
- Jornay PM 20mg capsules (Bottle of 100) (Drug) $21.78
- BRINTELLIX (Drug) $18.30
- Dayvigo (Drug) $14.52
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Lexington
Mark Wright, M.d, M.D
Psychiatry — Payments: $619,046
Psychiatry $619,046
Dr. Steven Croley, Md, MD
Psychiatry — Payments: $111,876
Psychiatry $111,876
Syed Rizvi, M.d, M.D
Psychiatry — Payments: $17,719
Psychiatry $17,719
Dr. Paolo Cassano, Md, Phd, MD, PHD
Psychiatry — Payments: $12,649
Psychiatry $12,649
Kathleen Lundvall, Md, MD
Psychiatry — Payments: $9,100
Psychiatry $9,100
Dr. Getulio Tovar, M.d, M.D
Psychiatry — Payments: $9,055
Psychiatry $9,055